Introduction {#S1}
============

With the widely use of carbapenem antibiotics, carbapenem-resistant *Enterobacteriaceae* (CRE) have been increasingly detected worldwide. The production of carbapenemases is the leading cause of carbapenem resistance in CRE. *Klebsiella pneumoniae* carbapenemase (KPC) is currently the most widely spread carbapenemase in the world, including China ([@B18]), while *K. pneumoniae* is the main clinical species producing KPC ([@B33]). KPC-type β-lactamases could hydrolyze carbapenems and almost all β-lactam antibiotics, and traditional β-lactamase inhibitors have limited effects on KPC ([@B19]). In addition, isolates producing KPC are commonly resistant to many other clinical agents ([@B20]) due to the co-expression of several resistant determinants. Novel treatments for infections caused by KPC-producing *K. pneumoniae* (KPC-KP) are in urgent need.

Avibactam, a novel non-β-lactam β-lactamase inhibitor, had a spectrum of activity against β-lactamase of classes A (e.g., KPC), C (AmpC), and selected D (e.g., OXA-48) enzymes ([@B29]). The combination of ceftazidime-avibactam (*CAZ-AVI)* has been approved in clinical treatment for KPC-producing *Enterobacteriaceae* by the United States Food and Drug Administration (FDA) in 2015 ([@B11]). In China, injectable CAZ-AVI (ZAVICEFTA^®^) was recently (May 2019) approved for the treatment of complicated intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), caused by multidrug resistant Gram-negative bacteria.

In this study, we examined the CAZ-AVI susceptibility of KPC-KP from patients with no prior CAZ-AVI treatment history in China and evaluated the potential of isolates with reduced susceptibility to this combination to develop resistance through *in vitro* selection experiments.

Materials and Methods {#S2}
=====================

Collection and Identification of Carbapenem-Resistant *K. pneumoniae* {#S2.SS1}
---------------------------------------------------------------------

A total of 616 unique clinical *K. pneumoniae* displaying carbapenem resistance which were defined as any isolate displaying imipenem and/or meropenem MIC values of \>2 μg/ml based on CLSI guideline ([@B5]) were collected from September 2016 to June 2018 from six tertiary hospitals in six different cities in China including Chengdu (Southwest China), Kunming (Southwest China), Guangzhou (Southern China), Yinchuan (Northwest China), Suzhou (Eastern China), and Beijing (Northern China). Species identification was performed by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) method using the Bruker Daltonics MALDI Biotyper according to the instructions of manufacturer, and confirmed by 16S rRNA sequencing ([@B30]).

Detection of Carbapenemases, ESBLs and Analysis of Porin Encoding Genes {#S2.SS2}
-----------------------------------------------------------------------

Polymerase chain reaction (PCR) was performed to detect the presence of carbapenemase-encoding genes (*bla*~*KPC*~, *bla*~*NDM*~, *bla*~*IMP*~, *bla*~*VIM*~, *bla*~*OXA--48*~) ([@B2]), the extended-spectrum beta-lactamases (ESBLs) genes (*bla*~*CTX--M*~, *bla*~*SHV*~ and *bla*~*TEM*~) ([@B1]) and to amplify porin encoding genes (*ompK35* and *ompK36*) ([@B4]) in the carbapenem-resistant *K. pneumoniae*. The entire coding sequences for these genes were then amplified using previously published primers and conditions ([@B7]; [@B25]) and subjected to Sanger sequencing.

Determination of CAZ-AVI Minimal Inhibitory Concentrations {#S2.SS3}
----------------------------------------------------------

The CAZ-AVI minimal inhibitory concentrations (MICs) were determined using the broth microdilution method recommended by CLSI ([@B5]). *Escherichia coli* ATCC 25922 was used as quality control strain ([@B5]). MICs were interpreted according to CLSI breakpoints ([@B5]). A CAZ-AVI MIC of ≥4/4 μg/ml was used as the cut-off of reduced susceptibility to CAZ-AVI for this study ([@B26]).

Antimicrobial Susceptibility Testing {#S2.SS4}
------------------------------------

*In vitro* susceptibility of the isolates with reduced CAZ-AVI susceptibility against the commonly used clinical antimicrobials was evaluated by Phoenix 100 Automated Microbiology System and interpreted using CLSI ([@B5]) guidelines or European Committee on Antimicrobial Susceptibility Testing (EUCAST) (for moxifloxacin and colistin). A total of 20 antibiotics belonging to 11 classes of antimicrobials were tested, including carbapenems (imipenem and meropenem), ureidopenicillin (piperacillin), β-lactam/β-lactamase inhibitor complexes (amoxicillin-clavulanate, ampicillin-sulbactam, and piperacillin-tazobactam), cephalosporins (cefazolin, cefotaxime, ceftazidime, and cefepime), monocyclic β-lactams (aztreonam), aminoglycosides (gentamicin and amikacin), fluoroquinolones (ciprofloxacin, moxifloxacin and levofloxacin), folate metabolic pathway inhibitors (trimethoprim-sulfamethoxazole), chloramphenicol, colistin, and tetracycline.

Collection of Clinical Information {#S2.SS5}
----------------------------------

The clinical information including city, age range, isolation date, clinical department, sample, medical condition and outcome of the patients from whom the carbapenem-resistant *K. pneumoniae* was isolated was collected using EPIINFO software based on the medical records.

Multilocus Sequence Typing (MLST) {#S2.SS6}
---------------------------------

Multilocus sequence typing (MLST) was conducted to investigate the genetic relationships of the isolates with reduced CAZ-AVI susceptibility. PCR followed by Sanger sequencing was used to detect conserved housekeeping including *gapA*, *infB*, *mdh*, *pgi*, *phoE*, *rpoB*, and *tonB* ([@B9]). Allelic profiles and sequence types (STs) were determined using the *K. pneumoniae* MLST database^[1](#footnote1){ref-type="fn"}^.

Pulsed-Field Gel Electrophoresis (PFGE) {#S2.SS7}
---------------------------------------

The clonal relatedness between the isolates with reduced CAZ-AVI susceptibility was investigated by pulsed-field gel electrophoresis (PFGE) with XbaI-digested DNA using a CHEF Mapper Power Module instrument (Bio-Rad, United States). Conditions of electrophoresis were as follow: voltage 6V/cm, running time 20 h, temperature 14°C, and pulse times of 1--40 s. *Salmonella enterica* serotype Braenderup H9812 was used as size marker. The results were evaluated using GelJ v.2.0 analyzing software.

Investigation of the Capsular Types and Virulence Genes {#S2.SS8}
-------------------------------------------------------

Multiplex PCR-II analysis was applied to investigate the capsular types including K1, K2, KL64, KL47 ([@B31]), and multiplex PCR-III analysis was performed to detect four virulence genes previously described on the pLVPK virulence plasmid namely *rmpA*, *rmpA2*, *iroN*, and *iutA* ([@B31]) in the isolates with reduced CAZ-AVI susceptibility.

Quantitative Real-Time PCR (qRT-PCR) and *bla*~*KPC*~ Promoter Region Sequencing {#S2.SS9}
--------------------------------------------------------------------------------

A total of 16 isolates, including 8 isolates with reduced susceptibility and 8 randomly selected susceptible isolates, were examined by quantitative real-time PCR (qRT-PCR) to assess the *bla*~*KPC--2*~ copy numbers relative to an internal *K. pneumoniae* housekeeping gene, *rpoB*, as previously described ([@B16]). The expression of *bla*~*KPC--2*~ in the same isolate set was measured using DNA-free RNA preparations by qRT-PCR as described previously ([@B24]; [@B10]). The statistical software used in this study was Prism 5 (Graph Pad Software). In addition, the *bla*~*KPC*~ promoter regions from 12 isolates with reduced CAZ-AVI susceptibility and the 8 randomly selected susceptible isolates were amplified and sequenced using the primers (KPCpro-F, 5′-AACGGTCGTATCAGCGACAT-3′ and KPCpro-R, 5′-CGAGTTTAGCGAATGGTTCC-3′), covering the previously described promoter regions in KPC-KP isolates from China ([@B15]).

*In vitro* Selection Testing {#S2.SS10}
----------------------------

All isolates underwent qRT-PCR detection, except for the CAZ-AVI (MIC 16/4 μg/ml) resistant isolate (*n* = 15), were subject to *in vitro* CAZ-AVI selective pressure testing, using a previously described method ([@B22]). The 15 strains included 7 isolates with reduced susceptibility (MIC ≥ 4/4 μg/ml) and 8 randomly selected susceptible isolates (see above). In brief, *in vitro* selection was performed by inoculation of ∼10^8^ cfu in 2-ml LB broth containing CAZ-AVI at the 0.5 × MICs followed by incubation for 24 h. This procedure was repeated daily, each time doubling the CAZ-AVI concentration up to a maximum of 8/4 μg/ml. Selected colonies collected at different *in vitro* selection antibiotic levels were subject to CAZ-AVI susceptibility testing. The isolates with increased MICs ≥ 16/4 μg/ml after CAZ-AVI selection were determined as selected CAZ-AVI resistance.

Results {#S3}
=======

Distribution of the KPC-KP {#S3.SS1}
--------------------------

The 616 non-duplicate clinical *K. pneumoniae* collected from September 2016 to June 2018 were from Chengdu (226, 36.7%, Southwest China), Kunming (148, 24.0%, Southwest China), Guangzhou (90, 14.6%, Southern China), Yinchuan (62, 10.1%, Northwest China), Suzhou (47, 7.6%, Eastern China), and Beijing (43, 7.0%, Northern China). In this collection 347 (56.3%) *K. pneumoniae* contained *bla*~*KPC*~, without coexistence of metallo-β-lactamases genes, the majority of which were from Kunming (119, 34.3%) followed by Chengdu (97, 28.0%), Guangzhou (49, 14.1%), Beijing (34, 9.8%), Suzhou (25, 7.2%), and Yinchuan (23, 6.6%) ([Table 1](#T1){ref-type="table"}).

###### 

Distribution of the regions and ceftazidime-avibactam MICs of the KPC-KP.

  **Regions**   **No. (%) of *K. pneumoniae***   **No. (%) of KPC-KP**   **No. (cumulative %) of KPC-KP inhibited at ceftazidime-avibactam MIC (μg/ml)**   **MIC~50~ (μg/ml)**   **MIC~90~ (μg/ml)**                                                                       
  ------------- -------------------------------- ----------------------- --------------------------------------------------------------------------------- --------------------- --------------------- ------------ ------------ ----------- ----------- ----------- ----- -----
  Beijing       43 (7.0)                         34 (79.1)               --                                                                                3 (8.8)               4 (20.6)              16 (67.6)    5 (82.4)     3 (91.2)    3 (100.0)   --          1/4   2/4
  Chengdu       226 (36.7)                       97 (42.9)               2 (2.1)                                                                           6 (8.2)               10 (18.6)             38 (57.7)    41 (100)     --          --          --          1/4   2/4
  Guangzhou     90 (14.6)                        49 (54.4)               --                                                                                4 (8.2)               2 (12.2)              20 (53.1)    21 (95.9)    2 (100.0)   --                      1/4   2/4
  Kunming       148 (24.0)                       119 (80.4)              3 (2.5)                                                                           1 (3.4)               6 (8.4)               68 (65.5)    38 (97.5)    --          2 (99.2)    1 (100.0)   1/4   2/4
  Yinchuan      62 (10.1)                        23 (37.1)               --                                                                                1 (4.3)               4 (21.7)              6 (47.8)     12 (100.0)   --          --          --          2/4   2/4
  Suzhou        47 (7.6)                         25 (53.2)               1 (4.0)                                                                           1 (8.0)               4 (24.0)              13 (76.0)    5 (96.0)     1 (100.0)   --          --          1/4   2/4
  **Total**     616 (100.0)                      347 (56.3)              6 (1.7)                                                                           16 (6.3)              30 (15.0)             161 (61.4)   122 (96.5)   6 (98.3)    5 (99.7)    1 (100.0)   1/4   2/4

--, no isolates.

Antimicrobial Susceptibility of KPC-KP {#S3.SS2}
--------------------------------------

Minimal inhibitory concentrations of CAZ-AVI inhibiting KPC-KP ranged from ≤0.125/4 to 16/4 μg/ml, with only one strain which was resistant (16/4 μg/ml) according to the CLSI breakpoint ([@B5]). The MIC~50~ was 1/4 μg/ml and MIC~90~ was 2/4 μg/ml ([Table 1](#T1){ref-type="table"}). We then used CAZ-AVI MIC of ≥4/4 μg/ml as the cut-off of reduced susceptibility to CAZ-AVI for this study ([@B26]). A total of 12 KPC-KP were found to have a CAZ-AVI MIC value ≥ 4/4 μg/ml with high level resistance to carbapenems (meropenem MICs ≥ 256 μg/ml) ([Table 1](#T1){ref-type="table"}).

These 12 isolates showed resistance to nearly all tested antimicrobials except trimethoprim-sulfamethoxazole (41.7%), chloramphenicol (16.7%), colistin (0%), and tetracycline (41.7%) ([Table 2](#T2){ref-type="table"}).

###### 

Susceptibility of the 12 isolates against different antimicrobial agents.

  **Antimicrobial agent^a^**   **Resistance^b^ (\[n\] %)**   **MIC (μg/ml)**   
  ---------------------------- ----------------------------- ----------------- --------
  IPM                          12 (100)                      \>8               \>8
  MEM                          12 (100)                      \>8               \>8
  PIP                          12 (100)                      \>64              \>64
  AMC                          12 (100)                      \>16/8            \>16/8
  SAM                          12 (100)                      \>16/8            \>16/8
  TZP                          12 (100)                      \>64/4            \>64/4
  CZO                          12 (100)                      \>16              \>16
  CTX                          12 (100)                      \>32              \>32
  CAZ                          12 (100)                      \>16              \>16
  FEP                          12 (100)                      \>16              \>16
  ATM                          12 (100)                      \>16              \>16
  GEN                          12 (100)                      \>8               \>8
  AMK                          12 (100)                      \>32              \>32
  CIP                          12 (100)                      \>2               \>2
  MXF                          12 (100)                      \>4               \>4
  lEV                          12 (100)                      \>8               \>8
  SXT                          5 (41.7)                      ≤0.5/9            \>2/38
  C                            2 (16.7)                      ≤4                \>16
  CL                           0 (0)                         ≤0.5              ≤0.5
  TET                          5 (41.7)                      8                 \>8

a

IPM, imipenem; MEM, meropenem; PIP, piperacillin; AMC, amoxicillin-clavulanate; SAM, ampicillin-sulbactam; TZP, piperacillin-tazobactam, CZO, cefazolin; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; ATM, aztreonam; GEN, gentamicin; AMK, amikacin; CIP, ciprofloxacin; MXF, moxifloxacin; LEV, levofloxacin; SXT, trimethoprim-sulfamethoxazole; C, chloramphenicol; CL, colistin; TET, tetracycline.

b

CLSI M100-S28 interpretive criteria were used in all cases, with the exception of MXF and CL, for which EUCAST breakpoints were used.

Clinical Information {#S3.SS3}
--------------------

The 12 isolates were obtained from distinct patients aged between 0 and 65 years old. They were from Beijing (*n* = 6), Kunming (*n* = 3), Guangzhou (*n* = 2), and Suzhou (*n* = 1). Four out of six Beijing isolates were collected from patients in ICU wards within the same month. In addition, most of these patients received empirical antibiotic treatments before these isolation of strains. Among them, carbapenems were the most commonly used antibiotic, followed by piperacillin-tazobactam ([Table 3](#T3){ref-type="table"}).

###### 

Clinical information of the 12 patients connected with the isolates with reduced susceptibility to ceftazidime-avibactam.

  **No.**   **City**    **Age range (y)**   **Isolated date**   **Clinical department**            **Source**          **Antibiotic treatment before isolated**            **Carbapenem usage (days)**    **Outcome**
  --------- ----------- ------------------- ------------------- ---------------------------------- ------------------- --------------------------------------------------- ------------------------------ ---------------
  1758      Beijing     55--60              Mar. 2017           ICU                                Respiratory tract   Carbapenems                                         Meropenem (3)                  Deterioration
  1762      Beijing     30--35              Mar. 2017           ICU                                Blood               Carbapenems                                         Meropenem (5) + Imipenem (5)   Improve
  1764      Beijing     35--40              Mar. 2017           ICU                                Intra-abdominal     Piperacillin-tazobactam, cephalosporin              --                             Improve
  1768      Beijing     45--50              Mar. 2017           ICU                                Respiratory tract   Carbapenems, piperacillin-tazobactam, tigecycline   Meropenem (11)                 Improve
  2321      Beijing     35--40              Apr. 2017           General ward                       Blood               Carbapenems                                         Imipenem (5)                   Cure
  2322      Beijing     35--40              Apr. 2017           General ward                       Respiratory tract   Carbapenems                                         Imipenem (5)                   Cure
  2477      Kunming     0--1                Sep. 2017           General ward                       Urinary tract       Fluoroquinolone                                     --                             Improve
  2789      Kunming     0--1                Oct. 2017           General ward                       Urinary tract       Piperacillin-tazobactam                             --                             Improve
  2827      Kunming     0--1                Nov. 2017           General ward                       Urinary tract       Piperacillin-tazobactam                             --                             Deterioration
  1706      Guangzhou   60--65              Feb. 2017           ICU                                Blood               Carbapenems, piperacillin-tazobactam, vancomycin    Meropenem (7) + Imipenem (1)   Improve
  5152      Guangzhou   55--60              Sep. 2018           Organ transplantation department   Blood               Not clear                                           --                             Not clear
  3855      Suzhou      45--50              Apr. 2018           General ward                       Intra-abdominal     Fluoroquinolone                                     --                             Improve

"--", no carbapenems was used.

Detection of ESBL and Virulence Genes and Capsular Genotyping {#S3.SS4}
-------------------------------------------------------------

These 12 isolates contain ESBLs genes including *bla*~*CTX--M--65*~ (*n* = 9), *bla*~*CTX--M--14*~ (*n* = 3) and *bla*~*SHV--12*~ (*n* = 8). In addition, the results of multiplex PCR showed that 6 isolates from Beijing were positive for the four virulence genes, namely *rmpA*, *rmpA2*, *iroN*, and *iutA*. Eight isolates belonged to capsular type KL64 and the other 4 isolates were from KL47 ([Table 4](#T4){ref-type="table"}).

###### 

Molecular characteristics of the 12 KPC-KP with reduced susceptibility to ceftazidime-avibactam.

  **No.**   **β-lactamases genes**                                     **Virulence genes**              **Sequence type**   **Capsular type**   **OmpK35**   **OmpK36**
  --------- ---------------------------------------------------------- -------------------------------- ------------------- ------------------- ------------ ------------
  1758      *bla*~*KPC--2*~, *bla*~*CTX--M--65*~, *bla*~*SHV--12*~     *rmpA*, *rmpA2*,*iutA*, *iroN*   ST11                KL64                Stop codon   134-135 GD
  1762      *bla*~*KPC--2*~, *bla*~*CTX*~*~--M--65~, bla*~*SHV--12*~   *rmpA*, *rmpA2*,*iutA*, *iroN*   ST 11               KL64                Stop codon   134-135 GD
  1764      *bla*~*KPC--2*~, *bla*~*CTX--M--65*~, *bla*~*SHV--12*~     *rmpA*, *rmpA2*,*iutA*, *iroN*   ST 11               KL64                Stop codon   134-135 GD
  1768      *bla*~*KPC--2*~, *bla*~*CTX*~*~--M--65~*                   *rmpA*, *rmpA2*,*iutA*, *iroN*   ST 11               KL64                Stop codon   134-135 GD
  2321      *bla*~*KPC--2*~, *bla*~*CTX--M--65*~, *bla*~*SHV--12*~     *rmpA*, *rmpA2*,*iutA*, *iroN*   ST 11               KL64                Stop codon   134-135 GD
  2322      *bla*~*KPC--2*~, *bla*~*CTX--M--65*~, *bla*~*SHV--12*~     *rmpA*, *rmpA2*,*iutA*, *iroN*   ST 11               KL64                Stop codon   134-135 GD
  2477      *bla*~*KPC--2*~, *bla*~*CTX--M--14*~, *bla*~*SHV--12*~     --                               ST 11               KL47                Stop codon   134-135 GD
  2789      *bla*~*KPC--2*~, *bla*~*CTX--M--14*~                       --                               ST 11               KL47                Stop codon   134-135 GD
  2827      *bla*~*KPC--2*~, *bla*~*CTX--M--14*~, *bla*~*SHV--12*~     --                               ST 11               KL47                Stop codon   134-135 GD
  1706      *bla*~*KPC--2*~, *bla*~*CTX--M--65*~, *bla*~*SHV--12*~     --                               ST 11               KL64                Stop codon   134-135 GD
  5152      *bla*~*KPC--2*~, *bla*~*CTX--M--65*~                       --                               ST 11               KL47                Stop codon   134-135 GD
  3855      *bla*~*KPC--2*~, *bla*~*CTX--M--65*~                       --                               ST 11               KL64                Stop codon   134-135 GD

"--", negative for PCR detection.

MLST Sequence Types and PFGE Patterns {#S3.SS5}
-------------------------------------

Multilocus sequence typing results showed that all 12 isolates belonged to ST11. Furthermore, these 12 isolates were investigated by PFGE. As shown in [Figure 1](#F1){ref-type="fig"}, the 6 isolates from Beijing shared the same PFGE pattern. In addition, 2 of the 3 isolates from Kunming were highly homologous (\>90%, dice similarity coefficient). The other isolates demonstrated different pulsotypes.

![PFGE cluster analysis of the 12 KPC-KP with reduced susceptibility to ceftazidime-avibactam. 1758, 1762, 1764, 1768, 2321, and 2322 were from Beijing sharing the same PFGE pattern. 2477, 2789, and 2827 were from Kunming, among which 2789 and 2827 were highly homologous (\>90%). 1706 and 5152 were from Guangzhou. 3855 was from Suzhou.](fmicb-11-01365-g001){#F1}

Outer Membrance Porin Gene Sequence Analysis {#S3.SS6}
--------------------------------------------

Sequencing of the outer membrane porin genes *ompK35* and *ompK36* showed that all 12 isolates contain a mutant OmpK35, with a premature stop codon at amino acid position 63, as well as a mutant OmpK36, due to the glycine and aspartic acid duplication at amino acid 134 (134--135 GD insertion). However, the OmpK35 and OmpK36 gene sequences of 8 randomly selected susceptible *K. pneumoniae* ST11 isolates showed the same genotypes (OmpK35 stop codon and OmpK36 134--135 GD insertion) as those of the 12 isolates with reduced CAZ/AVI susceptibility.

Mechanism of Reduced CAZ-AVI Susceptibility {#S3.SS7}
-------------------------------------------

Polymerase chain reaction detection and Sanger sequencing showed that the 12 isolates all harbored wild-type *bla*~*KPC--2*~. Examination of the *bla*~*KPC--2*~ promoter regions failed to identify any mutations in comparison to the sequences from the susceptible strains. The results of qRT-PCR showed that the relative *bla*~*KPC--2*~ copy numbers in the reduced susceptibility group were significantly higher than those in the susceptibility group (2.6-fold, *P* = 0.0004) ([Figure 2A](#F2){ref-type="fig"}). In addition, the relative expressions of *bla*~*KPC--2*~ in the reduced susceptibility group were 3.9-fold higher than those in the susceptibility group (*P* = 0.0034) ([Figure 2B](#F2){ref-type="fig"}).

![Relative *bla*~*KPC--2*~ copy numbers and expressions in susceptible and reduced susceptibility isolates. **(A)** Relative *bla*~*KPC--2*~ copy numbers in selected isolates. \*\*\**P* = 0.0004, Unpaired *t* test with Welch's correction. **(B)** Relative *bla*~*KPC--2*~ expressions in selected isolates. \*\**P* = 0.0034, Unpaired *t* test with Welch's correction.](fmicb-11-01365-g002){#F2}

*In vitro* Selection Testing {#S3.SS8}
----------------------------

The *in vitro* selection experiments showed that 4 of the 7 isolates with reduced susceptibility developed resistance to CAZ-AVI at the selection concentration of 2/4 μg/ml, and all 7 isolates developed resistance to CAZ-AVI with MICs ranging from 32/4 to 256/4 μg/ml when the selection concentration reached 4/4 μg/ml. By contrast, no isolates were developed to be resistance to CAZ-AVI in the susceptibility group, and all eight isolates stopped growing when the selection concentration reached 8/4 μg/ml.

Discussion {#S4}
==========

At present time, KPCs are the most common carbapenemases identified worldwide especially in *K. pneumoniae* from China ([@B18]). Due to the limited therapies, the detection rate of KPC-KP in China demonstrated a continuous upward trend ([@B14]). In this study, CAZ-AVI showed potent *in vitro* activities against KPC-KP, which agreed with previous studies ([@B8]; [@B28]). However, ∼3% isolates displayed reduced susceptibility to CAZ-AVI (MIC ≥ 4/4 μg/ml) despite they were obtained from patients without previous CAZ-AVI treatment history. Notably, these isolates also showed high level resistance to carbapenems.

In 2018, a fatal outbreak caused by ST11 KPC-KP with acquisition of a pLVPK-like virulence plasmid that increased the virulence of these isolates was reported ([@B13]). In our study, half of the isolates with reduced CAZ-AVI susceptibility contained several known virulence genes, suggesting that these isolates may have increased virulence, which should be closely monitored.

Since the previously reported gene mutations (e.g., D179Y) associated to CAZ-AVI resistance ([@B12]) weren't found in the *bla*~*KPC--2*~ genes, this study suggested that mechanisms other than *bla*~*KPC--2*~ gene mutation were underlying the reduced CAZ-AVI susceptibility among these isolates. OmpK35/36 defects had previously been reported to lead to reduced susceptibility or resistance to CAZ-AVI in KPC-KP ([@B17]). In this study, our results showed 12 isolates with reduced CAZ-AVI susceptibility contained OmpK35 and OmpK36 gene mutations, however, the same gene mutations were also found in the susceptible strains, which suggested that OmpK35/36 defects may only partially contribute to the reduced CAZ-AVI susceptibility among those 12 strains, while additional mechanisms may be involved. Our results demonstrated that the *bla*~*KPC--2*~ copy numbers and expressions in the reduced susceptibility group were significantly higher than those in the susceptibility group. We therefore suspected that the reduced CAZ-AVI susceptibility in these strains was likely due to the higher *bla*~*KPC--2*~ copy numbers and gene expressions, in combination to the OmpK35/36 defects. The results were consistent with some previously published studies ([@B26]; [@B32]). The higher copy numbers of *bla*~*KPC--2*~ may potentially result from the high copy numbers of the plasmids carrying *bla*~*KPC*~ ([@B23]) and/or a duplication of mobile genetic elements associated with *bla*~*KPC*~ ([@B6]). Since the examination of the *bla*~*KPC--2*~ promoter regions failed to identify any mutations, the higher *bla*~*KPC*~ gene expression may potentially be affected by the higher copy numbers of *bla*~*KPC*~ or other gene regulatory mechanisms. Further studies, including whole genome sequences, are needed to explore the molecular mechanisms underlying the higher *bla*~*KPC--2*~ copy numbers and gene expressions among those strains.

[@B27] has reported on the acquisition of CAZ-AVI resistance among ST258 KPC-KP during treatment in the United States. After that, ([@B21]) isolated a ST39 KPC-KP that was resistant to CAZ-AVI after this combination treatment. In China, ST11 KPC-KP is commonly prevalent ([@B3]; [@B33]). In this study, the ST11 KPC-KP with reduced susceptibility were more prone to develop CAZ-AVI resistance compared to susceptible isolates under the pressure of CAZ-AVI exposing.

Taken together, our study demonstrated that CAZ-AVI has potent *in vitro* activities against KPC-KP in China and highlighted the clinical significance of the isolates with reduced susceptibility to CAZ-AVI isolated from patients without previous CAZ-AVI treatment history. Our results suggested that the optimal clinical usage of CAZ-AVI should be guided by the *in vitro* susceptibility results in order to prevent selection resistance.
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